Clinical Significance of Measuring Serum p53 Antibodies in Colorectal Cancer Patients

Mitsuyoshi Ota, Shoichi Fujii, Yasushi Ichikawa, Hirokazu Suwa, Kenji Tatsumi, Kazuteru Watanabe, Shigeru Yamagishi, Kuniya Tanaka, Hirotoshi Akiyama and Itaru Endo

Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine

To evaluate the clinical significance of the serum p53 antibody in colorectal cancers, we preoperatively measured tumor markers, including the serum p53 antibody in 251 cases of colorectal cancer and compared them to patient profiles. Tumor markers were 31.2% positive for CEA, 15.8% positive for CA 19-9, and 31.6% positive for p53. The percentage of more than one of these markers being positive was 60.0%. In patients with fecal occult blood, p53 antibodies were significantly more positive than CEA (p=0.0215). In stage I subjects, p53 antibodies were significantly higher than CEA (p=0.0003). In 28 cases of synchronous multiple cancer, p53 antibodies were positive in 53.6% significantly higher than in those with single cancer. In 8 cases of synchronous double cancer, positive p53 antibodies were 50%. These results indicate the need to carefully check for synchronous multiple and double cancer in subjects in whom p53 antibodies are positive.

Key words
p53 antibody, colorectal cancer, multiple cancer

Reprint requests
Mitsuyoshi Ota Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine
3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004 JAPAN

Accepted
January 27, 2010

To read the PDF file you will need Abobe Reader installed on your computer.